Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
KN026 is an anti-HER2 bispecific antibody that can simultaneously bind two non-overlapping epitopes of HER2, leading to a dual HER2 signal blockade.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female subject \>= 18 years;
Histologically or cytologically confirmed, metastatic or locally advanced unresectable HER2-positive;
Adequate organ function assessed within 7 days prior to first trial treatment
ECOG score 0 or 1;
Left ventricular ejection fraction (LVEF) ≥ 50% at baseline;
Life expectancy \>3 months
You may not be if
Untreated active CNS metastasis or leptomeningeal metastasis;
Uncontrolled tumor-related pain;
Has received other anti-tumor treatment or an investigational drug within 28 days or within 5 times of half-life (whichever is shorter, and no less than 2 weeks) prior to the first trial treatment;
Major surgery for any reason within 28 days;
Curative radiation within 3 months of the first dose of trial treatment;
History of uncontrolled intercurrent illness;
Other medical conditions that at the discretion of investigator interfere with the requirements of the trial in terms of safety or efficacy evaluation, or treatment compliance
Clareo Health | Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer
